WO2010059554A2 - Composition et procédé pour le traitement des ecchymoses - Google Patents

Composition et procédé pour le traitement des ecchymoses Download PDF

Info

Publication number
WO2010059554A2
WO2010059554A2 PCT/US2009/064541 US2009064541W WO2010059554A2 WO 2010059554 A2 WO2010059554 A2 WO 2010059554A2 US 2009064541 W US2009064541 W US 2009064541W WO 2010059554 A2 WO2010059554 A2 WO 2010059554A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin treatment
vitamin
protease
skin
Prior art date
Application number
PCT/US2009/064541
Other languages
English (en)
Other versions
WO2010059554A3 (fr
Inventor
Joel R. Studin
Original Assignee
Studin Joel R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Studin Joel R filed Critical Studin Joel R
Publication of WO2010059554A2 publication Critical patent/WO2010059554A2/fr
Publication of WO2010059554A3 publication Critical patent/WO2010059554A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • This invention relates generally to skin treatment compositions and methods of skin treatment. Specifically, this invention relates to compositions and methods for skin treatment, wherein the compositions may be administered orally or topically. More specifically, this invention relates to compositions and methods for treatment of bruising, swelling and pain that often occurs after surgery or skin injury.
  • Hemosiderin is an abnormal microscopic pigment composed of iron oxide that can accumulate in different organs in various diseases or conditions.
  • the skin experiences a shock that breaks small blood vessels.
  • the red blood cells die and the hemoglobin is released from them into the extracellular space.
  • White blood cells called macrophages engulf the hemoglobin to degrade it, producing hemosiderin and porphyrin.
  • Hemosiderin accumulated under the skin causes black, blue and reddish appearance of a bruise.
  • Topical formulations directed towards improvement of bruising have been known.
  • U.S. Publication 2007/0243132 A1 to Russell-Jones et al. discloses microemulsions to be delivered transdermal ⁇ with a purpose of treating inflammations associated with bruising.
  • U.S. Publication 2004/0131579 A1 to Duraiswami et al. discloses a topical composition that is meant to reduce the duration and severity of bruising.
  • Nutritional supplements meant to improve healing after surgery or injury have also been known (e.g. U.S. Patent 7,205,007 B2 and U.S. Publication 2007/0160591 A1 to Lane). These formulations do not address the basic problem that causes the staining of the skin. They do not help to remove hemosiderin left over from blood from ruptured blood vessels
  • compositions that are to be administered orally would be particularly beneficial for the intended purpose as formulations applied to skin can be subjected to easy removal or oxidation of active ingredients before they are absorbed by skin.
  • the object of the invention is to provide a homeopathic skin treatment composition and method that minimize bruising and help to shorten the duration of bruising.
  • a skin treatment composition for oral or topical administration comprising a chelating agent and at least one protease.
  • a composition for oral or topical administration comprising a chelating agent, at least one protease and Arnica montana extract.
  • a method for skin treatment comprising oral or topical administration of a composition comprising a chelating agent and at least one protease.
  • a method for skin treatment comprising oral or topical administration of a composition comprising a chelating agent, at least one protease and Arnica montana extract.
  • This invention provides a skin treatment homeopathic composition for oral or topical administration as well as a method for skin treatment, comprising oral or topical administration of the composition.
  • the skin treatment composition of this invention reduces time that is necessary for hemosiderin to be removed from the bruise and causes the bruise coloring to fade. It also reduces inflammation and pain resulting from surgery or skin injury.
  • the skin treatment composition of this invention comprises a chelating agent and at least one protease.
  • the chelating agent is phytic acid and the protease is bromelain.
  • the composition may further comprise vitamins, enzymes, minerals and natural extracts.
  • the composition may be provided in a form of a kit.
  • Phytic acid, a protease and the remaining ingredients may be provided in a separate dosage form and Arnica montana extract in a separate dosage form.
  • the composition includes: about 25-75 mg phytic acid, about 150-300 mg bromelain, about 50-100 mg rutin, about 2-3 mg zinc, about 30-40 mg pine bark extract, about 10-15 meg vitamin K, about 100-150 mg vitamin C, about 30-40 I. U. vitamin E, and about 5-15 mg Coenzyme Q10.
  • the composition may also include about 30c Arnica montana extract or 1 M Arnica Montana extract.
  • the composition of this invention includes: about 50 mg phytic acid, about 250 mg bromelain, about 84 mg rutin, about 2.5 mg zinc, about 34 mg pine tree bark extract, about 12 meg vitamin K, about 125 mg vitamin C, about 34 I. U. vitamin E, and about 8.5 mg coenzyme Q10.
  • the composition may also include about 30c Arnica montana extract or 1 M Arnica Montana extract.
  • a chelating agent that is preferably used in this invention is phytic acid.
  • Phytic acid is a phosphorylated alcohol also known as inositol hexaphosphate or IP6 (inositol-1 ,2,3,4,5,6,-hexakisphosphate). It is found in whole grains, soybeans, seeds and nuts.
  • IP6 inositol hexaphosphate
  • the preferred phytic acid is the one that is 70% unbound, such as the one processed from rice bran and produced by Tsuno Foods & Rice Co., Wakayama, Japan.
  • the highly unbound phytic acid selectively attaches to minerals as it enters the human circulatory system. It attaches to unbound compounds of iron, copper, calcium and heavy metals such as mercury, lead and cadmium.
  • Phytic acid has little or no affinity to sodium, potassium and magnesium, the important electrolyte minerals required for maintaining the proper heart rhythm. As it enters the circulatory system it attaches to hemosiderin that remains under the skin from ruptured blood vessels and causes the staining of bruised area. Once bound to phytic acid hemosiderin is removed from the human body through the urinary track, thereby causing the staining of the skin to fade.
  • the protease that is preferably included in the skin treatment composition of this invention is bromelain.
  • Bromelain also known as bromelin, is a proteolytic anti-inflammatory enzyme naturally found in the flesh and stems of the pineapple plant, Ananas comosus. It is particularly effective in relieving inflammation associated with surgery and physical injuries. It helps to reduce post-operative and post-injury swelling, pain and healing time. Bromelain inhibits prostaglandins that cause inflammation, which results in swelling and pain. By slowing down those prostaglandins bromelain promotes the formation of anti-inflammatory prostaglandins that induce lessening of swelling and pain.
  • the preferred potency of Bromelain for the purpose of this invention is 2000 GDU.
  • serrapeptase also known as serratio-peptidase or serrapeptidase. It is an enzyme extracted from Serratia marcescens, a bacteria found in the intestine of the silkworm. Serrapeptase is also present in fermentation extracts of Aspergillus oryzae and Aspergillus melleus, edible fungi. It is particularly useful as an anti-inflammatory as well as anti-edemic agent. It induces fibrinolytic activity in tissues thereby helping to remove blood clots. It promotes the removal of dead tissue. It generally helps with the healing process of injured tissues and reduces pain due to its ability to block the release of pain- inducing amines from inflamed tissues.
  • the composition of this invention is not limited to the use of phytic acid as a chelating agent.
  • Other suitable chelating agents may be employed in the composition.
  • other suitable proteases may be used in the composition of this invention.
  • Rutin also known as rutoside, quercetin-3-rutinoside or sophorin, is a member of bioflavonoids. It is most abundant in apricots, buckwheat, cherries, prunes, rosehips, the whitish rind of citrus fruits, core of green peppers and fruit of Fava D'Anta tree. It has the ability to strengthen and modulate the permeability of the walls of the blood vessels including capillaries. It strengthens the capillaries and is especially helpful in preventing recurrent bleeding and thereby further bruising caused by weakened blood vessels such as those that were subjected to a shock during surgery or injury. It is helpful for people who bruise or bleed easily.
  • Zinc has anti-oxidant properties and protects the skin against premature aging. It is essential for the synthesis of collagen. It helps in production of enzymes that are necessary for repair of skin wounds and bruises. It is helpful in healing of bruises by bolstering the immune system and helping to protect the body from infections.
  • Pine tree bark extract is obtained from the bark of a European coastal pine tree, Pinus maritina.
  • the pine tree bark is known for its antioxidant properties and for the ability to help in wound healing. It contains high amounts of bioflavonoids that have beneficial effects in improving circulation and repairing tissue.
  • Proanthocyanidins (OPCs) that are abundant in pine tree bark extract are some of the most powerful antioxidants available. They have been shown to help reduce swelling and inflammation in the body, protect cells from radical damage and increase the effectiveness of vitamin C. Pine tree bark extract has been shown to help strengthen and repair tissues made of collagen.
  • Vitamin K is found naturally in leafy greens, cauliflower and liver. At least two naturally occurring forms of vitamin K have been identified and they are designated as vitamins K 1 and K 2 . Both are quinone derivatives. Vitamin K is a necessary participant in synthesis of several proteins that promote blood coagulation, a property that is especially important in surgery or skin injury cases as it helps to prevent further bruising.
  • Vitamin C also known as ascorbic acid, is a highly effective antioxidant. It is necessary in formation of collagen and in prevention of extensive bleeding and bruising. Thus, it promotes healing of skin tissue. Additionally it protects molecules in the body, such as proteins, lipids and carbohydrates, from damage by free radicals.
  • Vitamin E is a group of 8 related tocopherols and tocotrienols, of which ⁇ - tocopherol has the highest bioavailability and is the form of vitamin E that is preferentially used and absorbed by the human body. Vitamin E is a powerful antioxidant protecting body cells from free radicals. It helps with tissue repair and improves healing of wounds.
  • Coenzyme Q10 (CoQI O) is a coenzyme in several of the key enzymatic steps critical in the production of adenosine triphosphate (ATP), a compound essential for production of energy in every cell of the human body.
  • Coenzyme Q10 helps to produce collagen, elastin, and other important skin molecules, thus helping to accelerate the healing process of injured skin. Additionally it functions as a powerful antioxidant. It is naturally present in organ meats such as heart, liver, kidney, as well as in beef, soybean oil, sardines and peanuts.
  • the composition of this invention also includes Arnica montana extract.
  • Arnica montana is a species containing helenalin, which is a sesquiterpene lactone possessing anti-inflammatory properties especially beneficial against bruising.
  • Arnica montana extract stimulates activity of white blood cells, thus causing reduction of bruising and swelling. It assists the healing process by facilitating transport of blood and fluid accumulated in the injured area through a dilating action of subcutaneous blood capillaries. It accelerates the healing of damaged tissues by encouraging immune cell function and shortens the recovery time after the surgery or injury.
  • the composition of this invention may be formulated in various dosage forms.
  • Arnica montana extract may be formulated in a tablet form while a chelating agent such as phytic acid and the remaining ingredients of the composition may be included in a capsule or a tablet form.
  • the tablets or capsules containing chelating agent such as phytic acid and at least one protease may be provided with enteric coating. Enteric coatings are placed on tablets or capsules to ensure that the tablet or a capsule does not dissolve until it reaches the small intestine. Enteric coatings usually do not dissolve in solutions with a pH lower than 5.5.
  • enteric coatings include: cellulose acetate, methacrylic acid copolymers, styrol maleic acid copolymers, polymethacrylic acid/acrylic acid copolymer, hydroxypropyl methylcellulose phtalate, polyvinyl acetate phtalate, hydroxyethyl ethylcelllulose phtalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate, tetrahydrophtalate, acrylic resin, and shellac.
  • Enteric coatings are first dissolved in an organic solvent such as acetone, methanol, ethanol, isopropyl alcohol and then applied to tablets or capsules by spraying or as chemical vapor, or are put in a rotating pan partially filled with coating. The solvent is then evaporated.
  • organic solvent such as acetone, methanol, ethanol, isopropyl alcohol
  • Tablets and capsules may be provided in a form of a kit. If provided in a form of a kit they should be administered consecutively within a period of time as short as reasonably practicable. Tablets containing Arnica montana extract should be administered sublingually and should be placed under the tongue and allowed to dissolve quickly while the tablets or capsules containing chelating agent such as phytic acid and the remaining ingredients of the composition may be swallowed with water. For optimum benefit the skin treatment should start as soon as therapeutically practicable and beneficial, usually immediately after surgery or injury.
  • An example of a single dosage is one tablet of Arnica montana extract and two tablets or two capsules comprising the remaining ingredients of the composition, to be taken three times per day. The daily dosage should be adjusted for each individual patient. The length of time that is necessary for the optimal results of the treatment varies with each individual case, however, the composition should be administered for at least 10 days.
  • the composition may be administered with help of a carrier in a form of an ointment, cream, lotion, gel, paste, solution, etc., and may contain liposomes, micelles, and/or microspheres.
  • Carriers useful in this invention include any such materials known in the art that are nontoxic and do not interact with other components of the composition in a deleterious manner.
  • Ointments as is well known in the art, are semisolid preparations based on petrolatum or petrolatum derivatives.
  • the specific ointment base to be used is one that will provide for optimum delivery of the composition and will provide other desirable characteristics, for example emoliency.
  • Ointment bases may also contain vegetable oils, fats obtained from animals or polyethylene glycols.
  • Creams are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil.
  • Cream bases contain an oil phase, an emulsifier, and an aqueous phase.
  • the oil phase generally comprises petrolatum and a fatty alcohol such as cetyl or stearyl alcohol.
  • the aqueous phase usually exceeds the oil phase in volume and may contain a humectant.
  • the emulsifier is generally a nonionic, anionic, cationic or amphoteric surfactant.
  • Gels are semi-solid suspension-type systems.
  • Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contains an alcohol and, optionally, an oil.
  • Preferred gelling agents are crosslinked acrylic acid polymers, such as the "carbomer" family of polymers. E.g. carboxypolyalkylenes.
  • hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol
  • cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and methylcellulose
  • gums such as tragacanth and xanthan gum, sodium alginate
  • gelatin In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, or stirring, or combination thereof.
  • Lotions are preparations to be applied to the skin surface without friction and are typically liquid or semiliquid preparation in which solid particles, including the active agents are present in a water or alcohol base. Lotions are usually suspensions of solids and preferably comprise a liquid oily emulsion of the oil-in- water type. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions typically contain suspending agents to produce better dispersion as well as compounds useful for localizing and holding the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethylcellulose, or the like.
  • Pastes are semisolid dosage forms in which the active agent is suspended in a suitable base. Depending on the nature of the base, pastes are divided between fatty pastes or those made from a single-phase aqueous gels.
  • the base in a fatty paste is generally petrolatum, hydrophilic petrolatum, or the like.
  • the pastes made from single-phase aqueous gels generally incorporate carboxymethylcellulose or the like as a base.
  • Formulations for topical administration may also be prepared with liposomes, micelles, and microspheres.
  • Liposomes are microscopic vesicles having a lipid wall comprising a lipid bilayer, and can be used for topical delivery of the present composition as well.
  • Liposomal preparations for use in this invention include cationic, anionic and neutral preparations.
  • Micelles are known as comprised of surfactant molecules arranged so that their polar headgroups form an outer spherical shell, while their hydrophobic hydrocarbon chains are oriented towards the center of the sphere forming a core. Micelles form in aqueous solution containing surfactant at a high enough concentration so that micelles naturally result.
  • Surfactants useful for forming micelles include, but are not limited to, potassium laurate, sodium octane sulfonate, sodium decane sulfonate, sodium lauryl sulfate, docusate sodium, decyltrimethylammonium bromide, dodecyltrimethylammonium bromide, tetradecyltrimethylammonium bromide, dodecyl ammonium chloride, polyoxyl 12 dodecyl ether, and nonoxynol 30.
  • Micelle formulations can be used in conjunction with the present invention either by incorporation into the reservoir of a topical delivery system, or into a formulation to be applied to the body surface.
  • Microspheres may also be used for topical administration of the composition of the present invention. Similarly, like liposomes and micelles, microspheres essentially encapsulate a composition to be applied on the skin. Microspheres are generally formed from synthetic or naturally occurring biocompatible polymers, but may also be comprised of charged lipids such as phospholipids.
  • a carrier or a base of any form of topical delivery should be biologically and chemically inert, non-toxic, non-irritating and not interacting with components of the composition. Additionally, a carrier should provide for deep penetration of the composition into the skin.
  • the skin treatment composition of this invention is a homeopathic composition comprising naturally derived ingredients, which can be used safely at the same time as conventional medicines, promoting accelerated time of recovery after surgery or skin injury, and guarding against staining of skin, swelling and pain.

Abstract

La présente invention concerne une composition de traitement de la peau pour administration orale ou topique et un procédé pour le traitement de la peau. La composition comprend un agent chélateur et au moins une protéase. La composition contribue à éliminer l’hémosidérine qui cause une coloration de la peau sur une ecchymose et réduit l’inflammation et la douleur.
PCT/US2009/064541 2008-11-18 2009-11-16 Composition et procédé pour le traitement des ecchymoses WO2010059554A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/273,311 2008-11-18
US12/273,311 US8309081B2 (en) 2008-11-18 2008-11-18 Composition and method for treatment of bruising

Publications (2)

Publication Number Publication Date
WO2010059554A2 true WO2010059554A2 (fr) 2010-05-27
WO2010059554A3 WO2010059554A3 (fr) 2010-07-15

Family

ID=42172215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064541 WO2010059554A2 (fr) 2008-11-18 2009-11-16 Composition et procédé pour le traitement des ecchymoses

Country Status (2)

Country Link
US (2) US8309081B2 (fr)
WO (1) WO2010059554A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149575A1 (fr) * 2010-05-28 2011-12-01 Nexgen Dermatologics, Inc. Compositions et procédés destinés au traitement d'ecchymoses
US10022335B2 (en) 2011-03-03 2018-07-17 Nancy Josephine Polich Homeopathic therapeutic method and compositions
BR112013028968A2 (pt) 2011-05-12 2018-04-24 Smith & Nephew Orthopaedics Ag composições de desbridamento de feridas contendo seaprose e métodos de tratamento de feridas utilizando-as
US10398643B2 (en) * 2016-05-13 2019-09-03 Kenneth Russell Transdermal administration of antioxidant for treatment of pain and inflammation
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
US10478466B1 (en) 2015-02-13 2019-11-19 Peter Kennedy Topical vasodilator composition
US20160235796A1 (en) * 2015-02-13 2016-08-18 Peter Kennedy Topical vasodilator composition
US10172847B2 (en) * 2016-05-13 2019-01-08 Kenneth Russell Method for reducing, inhibiting, and eliminating inflammation and pain with transdermal delivery of iron chelator composition
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
EP3573622B1 (fr) 2017-01-30 2023-10-18 Smith & Nephew, Inc. Combinaison synergique du thermolysin et d'un agent antibactérien pour réduire ou éliminer des biofilms sur des surfaces

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20040131579A1 (en) * 1998-09-10 2004-07-08 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20080213246A1 (en) * 2007-03-02 2008-09-04 Sam Ziff Supplements For Pain Management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260287A (en) * 1992-05-11 1993-11-09 Board Of Regents, The University Of Texas System Polyphosphorylated organic compounds: compositions useful in protecting biological tissues
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
WO2004093824A2 (fr) * 2003-04-08 2004-11-04 Fairfield Clinical Trials, Llc Supplementation nutritionnelle peri-operationnelle et peri-interventionnelle
US7588586B2 (en) * 2003-05-27 2009-09-15 Ethicon, Inc. Tissue fixation device
AU2006326870A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131579A1 (en) * 1998-09-10 2004-07-08 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20080213246A1 (en) * 2007-03-02 2008-09-04 Sam Ziff Supplements For Pain Management

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF KOREAN SOCIETY OF AESTHETIC PLASTIC SURGERY vol. 13, no. 2, September 2007, pages 151 - 158 *

Also Published As

Publication number Publication date
WO2010059554A3 (fr) 2010-07-15
US20100124549A1 (en) 2010-05-20
US8309081B2 (en) 2012-11-13
US20130028884A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
US8309081B2 (en) Composition and method for treatment of bruising
JP4889093B2 (ja) 皮膚疾患の処置および予防のための海綿動物ベースの治療用組成物
DE102008036954B4 (de) Verwendung einer Aminozucker enthaltenden Zusammensetzung
US20030157205A1 (en) Inhibitory and preventative effects of processed morinda citrifolia on mutagenesis and carcinogenesis in mammals
JP2010106022A (ja) セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤
US6242010B1 (en) Synergistic antioxidant compositions in management of hemorrhoids and other ano-rectal inflammatory conditions
JP2009514968A (ja) 腸管障害を制御するための組成物およびその使用方法
JP2008508301A (ja) エミュー油と果実の組成物
KR101550179B1 (ko) 탈모방지 및 모발성장 조성물
JP2010506893A (ja) 任意に少なくとも１種のポリフェノール化合物と組み合わせたグルコサミンの美容的経口及び／又は非経口使用、並びに対応組成物
US20020192314A1 (en) Dietary supplement compositions
EP0279984A2 (fr) Utilisation pharmaceutique des extraits de graminées
US20040254095A1 (en) Supplement for treating musculoskeletal disorders
CN107049911A (zh) 一种治疗红血丝的组合物及其应用
CN110420214A (zh) 一种防治脑缺血引起氧化应激反应的药物及其制剂
CA2346647C (fr) Traitement de la dyspepsie
CN110302263A (zh) 一种含金莲花成分的治疗口腔溃疡喷剂及其制备方法
CN113616587B (zh) 一种用于晒后皮肤修复的气雾剂及其制备方法
CN109248125A (zh) 一种含有蜂王浆提取物的天然滋润抗衰面膜
RU2277954C2 (ru) Крем для лица омолаживающий
US20120276174A1 (en) Therapeutic Treatment of Dermatologic Skin Disorders
KR101273518B1 (ko) 천연 발효 발모제 조성물 및 그 제조 방법
WO2006091804A2 (fr) Compositions et procedes pour le traitement de l'acne
Tyagi et al. Unlocking Radiance: The Dynamic Duo of Flaxseeds and Aloe Vera in Hair Mask for Bioactive Brilliance
CN106581663A (zh) 一种治疗激素依赖性皮炎的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09828073

Country of ref document: EP

Kind code of ref document: A2